IL13 and asthma: Moreover, the efficacy of anti-interleukin (IL)-5 and anti-IL-13 antibodies in severe asthma clearly demonstrates the need for both careful patient phenotyping and the need for reliable biomarkers of patient phenotypes and drug efficacy [7, 8].